Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Overview

Journal Int J Antimicrob Agents

Specialties Infectious Diseases
Pharmacology

Date 2023 May 28

PMID 37245600

Authors

Fangyuan Tian

Qiyi Feng

Zhaoyan Chen

Affiliations

Soon will be listed here.

Abstract

Introduction: There are currently some differences in the research results of molnupiravir. This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of COVID-19.

Methods: PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), ClinicalTrials.gov, ICTRP (International Clinical Trials Registry Platform) and medRxiv were searched to identify relevant randomised controlled trials (RCTs) from inception to 1 January 2023. The Cochrane risk of bias tool for randomised trials was used to assess the bias risk of the included studies. Revman 5.4 software was used for meta-analysis.

Results: Nine RCTs were included, including 31 573 COVID-19 patients, of whom 15 846 received molnupiravir. The meta-analysis results showed that the molnupiravir group had a higher proportion in terms of clinical improvement (Day 5 RR 2.41, 95% CI 1.18-4.92; Day 10 RR 1.45, 95% CI 1.04-2.01) and real-time polymerase chain reaction negativity (Day 5 RR 2.78, 95% CI 1.38-5.62; Day 10 RR 1.18, 95% CI 1.07-1.31). However, no significant difference was observed between the two groups in terms of mortality, hospitalisation, adverse events and serious adverse events.

Conclusions: Molnupiravir can accelerate the rehabilitation of COVID-19 patients, but it does not significantly reduce mortality and hospitalisation.

Citing Articles

The prevalence and factors associated with potentially inappropriate medications in Chinese older outpatients with heart failure.

Zhang Y, Chen Z, Tian F BMC Geriatr. 2024; 24(1):1040.

PMID: 39731041 PMC: 11673323. DOI: 10.1186/s12877-024-05630-w.

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.

Muthukutty P, MacDonald J, Yoo S Vaccines (Basel). 2024; 12(11).

PMID: 39591123 PMC: 11598775. DOI: 10.3390/vaccines12111220.

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis.

Chen Z, Tian F, Zhang Y Front Public Health. 2024; 12:1410355.

PMID: 38883194 PMC: 11177686. DOI: 10.3389/fpubh.2024.1410355.

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

Allerton C, Arcari J, Aschenbrenner L, Avery M, Bechle B, Behzadi M J Med Chem. 2024; 67(16):13550-13571.

PMID: 38687966 PMC: 11345836. DOI: 10.1021/acs.jmedchem.3c02469.

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.

Amani B, Amani B Immun Inflamm Dis. 2024; 12(4):e1262.

PMID: 38652021 PMC: 11037253. DOI: 10.1002/iid3.1262.

References

Dejmek M, Konkolova E, Eyer L, Strakova P, Svoboda P, Sala M . Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication. Viruses. 2021; 13(8). PMC: 8402726. DOI: 10.3390/v13081585. View

Amani B, Zareei S, Amani B . Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19. Br J Clin Pharmacol. 2022; 88(10):4403-4411. PMC: 9349444. DOI: 10.1111/bcp.15449. View

Tian F, Chen Z, Feng Q . Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023; 95(4):e28732. DOI: 10.1002/jmv.28732. View

Zou R, Peng L, Shu D, Zhao L, Lan J, Tan G . Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. Front Pharmacol. 2022; 13:939573. PMC: 9248931. DOI: 10.3389/fphar.2022.939573. View

Ledford H, Maxmen A . African clinical trial denied access to key COVID drug Paxlovid. Nature. 2022; 604(7906):412-413. DOI: 10.1038/d41586-022-00919-5. View

Hsu C, Chen C, Chen W, Lai C, Hung S, Lin W . Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2022; 59(3):106545. PMC: 8817946. DOI: 10.1016/j.ijantimicag.2022.106545. View

Butler C, Hobbs F, Gbinigie O, Rahman N, Hayward G, Richards D . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2022; 401(10373):281-293. PMC: 9779781. DOI: 10.1016/S0140-6736(22)02597-1. View

Khoo S, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards C . Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2022; 23(2):183-195. PMC: 9662684. DOI: 10.1016/S1473-3099(22)00644-2. View

Lee C, Hsieh C, Ko W . Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics (Basel). 2021; 10(11). PMC: 8614993. DOI: 10.3390/antibiotics10111294. View

10.

Wong C, Au I, Lau K, Lau E, Cowling B, Leung G . Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong.... Lancet. 2022; 400(10359):1213-1222. PMC: 9539539. DOI: 10.1016/S0140-6736(22)01586-0. View

11.

Hashemian S, Pourhanifeh M, Hamblin M, Shahrzad M, Mirzaei H . RdRp inhibitors and COVID-19: Is molnupiravir a good option?. Biomed Pharmacother. 2021; 146:112517. PMC: 8654603. DOI: 10.1016/j.biopha.2021.112517. View

12.

Caraco Y, Crofoot G, Moncada P, Galustyan A, Musungaie D, Payne B . Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evid. 2024; 1(2):EVIDoa2100043. DOI: 10.1056/EVIDoa2100043. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

14.

Yang H, Rao Z . Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021; 19(11):685-700. PMC: 8447893. DOI: 10.1038/s41579-021-00630-8. View

15.

Scholey J, Aburto J, Kashnitsky I, Kniffka M, Zhang L, Jaadla H . Life expectancy changes since COVID-19. Nat Hum Behav. 2022; 6(12):1649-1659. PMC: 9755047. DOI: 10.1038/s41562-022-01450-3. View

16.

Huang C, Lu T, Lin L . Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. Antibiotics (Basel). 2023; 12(2). PMC: 9952148. DOI: 10.3390/antibiotics12020393. View

17.

Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V . Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021; 386(6):509-520. PMC: 8693688. DOI: 10.1056/NEJMoa2116044. View

18.

Sinha S, N K, Suram V, Chary S, Naik S, Singh V . Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India. Cureus. 2022; 14(11):e31508. PMC: 9751243. DOI: 10.7759/cureus.31508. View

19.

Lawrence J, Mirchandani M, Hill A . Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis. J Antimicrob Chemother. 2023; 78(3):613-619. DOI: 10.1093/jac/dkac440. View

20.

Mollan K, Eron J, Krajewski T, Painter W, Duke E, Morse C . Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. Clin Infect Dis. 2022; 75(1):e1028-e1036. PMC: 9402664. DOI: 10.1093/cid/ciab968. View